Changes in D 2 -like dopamine (DA) receptor binding in rat
characteristic of antipsychotic drugs (Baldessarini 1996; Neve and Neve 1997) . There is a keen interest in developing novel antipsychotics with less adverse effects but similar or even superior beneficial effects on standard agents. A major step in that direction was the prototype agent clozapine, which has an atypically limited risk of adverse extrapyramidal effects or hyperprolactinemia as well as superior antipsychotic effectiveness (Baldessarini and Frankenburg 1991) . However, since use of clozapine is limited due to its high risk of potentially fatal bone marrow toxicity and other adverse effects, including excessive sedation and seizures, there is great interest in defining neuropharmacologic characteristics of clozapine that may lead to safer, improved antipsychotics.
Actions of clozapine that may contribute to its unique properties include antagonistic effects at serotonin 5-HT 2 and muscarinic acetylcholine receptors, balanced with moderate affinity for both D 1 and D 2 receptors (Baldessarini and Frankenburg 1991; Meltzer 1991; Brunello et al. 1995; Baldessarini 1996) . Clozapine also shows somewhat greater affinity for D 4 than for other DA receptors (Van Tol et al. 1991; Roth et al. 1995; Baldessarini et al. 1997; Kebabian et al. 1997) . Moreover, repeated treatment with clozapine results in selective upregulation of putative D 4 -like, but not D 2 , receptors in rat forebrain ). Interest in the D 4 receptor as a potential site of action of antipsychotic agents is further encouraged by observations suggesting that these sites may be upregulated in postmortem brain tissue of patients diagnosed with schizophrenia Murray et al. 1995; Sumiyoshi et al. 1995) . Interpretation of these findings remains tentative, however, due to uncertainty about the localization of D 4 receptors in mammalian brain (Baldessarini and Tarazi 1996) (Reynolds and Mason 1994, 1995; Lahti et al. 1995) , and there may be differences in relative abundance of D 4 protein and its mRNA between brain regions and across species (Van Tol et al. 1991; Schoots et al. 1995; Suzuki et al. 1995) . Clarification awaits development of improved D 4 -selective agents (Kebabian et al. 1997) or immunohistological techniques (Mrzljak et al. 1996) .
The DA partial-agonist derivatives, Campbell et al. 1985 Campbell et al. , 1986 Campbell et al. , 1991 , its orally active methylenedioxy prodrug, S( ϩ )-10,11-methylenedioxy-N-n -propylnoraporphine (Campbell et al. 1987 ) and 11-monohydroxy analog, S( ϩ )-11-hydroxy-N-n -propylnoraporphine (Gao et al. 1988; Campbell et al. 1990 ) have properties suggestive of atypical antipsychotics. These include inhibition of spontaneous or DA-induced locomotor arousal without catalepsy, weak antagonism of stereotyped gnawing behaviors induced by R( Ϫ )-aporphines, regional changes in brain concentrations of neurotensin similar to those of clozapine, and lack of hyperprolactinemia, tolerance, or induction of supersensitivity to DA agonists after repeated administration (Campbell et al. 1985 (Campbell et al. , 1986 (Campbell et al. , 1987 (Campbell et al. , 1993 Nemeroff et al. 1991; Baldessarini et al. 1994 ). Mechanisms underlying highly regionally selective behavioral actions of S( ϩ )-aporphines are not well defined, but selective interactions with D 4 receptors might be involved Lahti et al. 1993 Kebabian et al. 1997 ).
The present study was undertaken to verify D 4 selectivity of [ ϩ ]-NPA, and to test the hypothesis that it induces regionally selective changes in levels of different D 2 -like DA receptors resembling those of clozapine but not typical antipsychotics, and specifically to test for its long-term upregulation of D 4 -like sites. Effects of three weeks of daily administration of [ ϩ ]-NPA on D 2 -like receptor levels were compared to a typical neuroleptic, fluphenazine, and the atypical antipsychotic, clozapine, using quantitative in vitro receptor autoradiography.
METHODS

Materials and Animal Subjects
Radioligands were from New England Nuclear (Boston, MA): R,S( Ϯ )-[N-methyl- H] R( ϩ )-7-hydroxy-N,N-di-n -propyl-2-amino-1,2,3,4-tetrahydronaphthalene (7-OH-DPAT: 116 Ci/mmol) and [2, 3, H]spiperone (114 Ci/mmol). DTG (1,3-ditolylguanidine), S( Ϫ )-eticlopride-HCl, cisflupenthixol-di-HCl, fluphenazine-di-HCl, ketanserin tartrate, L-745,870, pindolol, and S( Ϫ )-sulpiride were from Research Biochemicals International (RBI, Natick, MA). (Campbell et al. 1993 ). (Baldessarini et al. 1992) . D 2 assays with cell membranes were conducted for 60 minutes at 27ЊC, and D 4 assays for 150 minutes at 25ЊC. Agents were tested at six or more concentrations in duplicate. Incubations were terminated by immersion in an ice bath, followed by rapid filtration in a cell harvester (Brandel, Gaithersburg, MD) on SS34 (for D 2 ) or SS32 (D 4 ) glass fiber filter sheets (Schleicher-Schuell, Keene, NH) impregnated with 0.3% (w/v) PEI; samples were counted in 3.5 ml Polyfluor (Packard, Downers Grove, IL) in a scintillation spectrophotometer (Wallace, Gaithersburg, MD) at ca. 50% efficiency. IC 50 Ϯ SE was obtained with the ALLFIT program to fit percent inhibition of specific binding vs. test agent concentration, and converted to Ki from the Cheng-Prusoff relationship, Ki ϭ IC 50 /(1 ϩ F/Kd), where F is free radioligand concentration and Kd is the independently determined radioligand affinity (Kd ϭ 0.22 nM in the D 2 , and 0.21 nM in the D 4 assay), all as described previously (Kula et al. 1994 ).
In Vitro Receptor Affinities
Drug Treatment and Tissue Preparation
Four groups of rats (N ϭ 7/group) received intraperitoneal (i.p.) injections at 1 ml/kg body wt daily for 21 days with doses defined as mg of salts. Two groups were injected once daily (08:00 h) with physiological saline (0.9% w/v) or fluphenazine-(HCl) 2 (1 mg/kg); a third received clozapine base (20 mg/kg, twice daily: 08:00 and 20:00 h); and a fourth received (ϩ)-NPA-HCl (2 mg/kg, thrice daily: 08:00, 14:00, and 20:00 h). At 24 h after final injections, rats were decapitated and their brains quickly removed, frozen in chilled isopentane, and stored at Ϫ80ЊC until use. Coronal sections (10 m) were cut from ca. 0.2-4.2 mm anterior to the bregma (Paxinos and Watson 1982) in a cryostat at Ϫ20ЊC, mounted on gelatin-coated microscopic slides, and stored at Ϫ20ЊC until thawed at room temperature (rt) for autoradiography.
Receptor Labeling for Autoradiography
To reduce variance, brain samples from subjects exposed to all treatment conditions were evaluated at one time in each radioreceptor assay, following preincubation of brain sections for 1 h at rt in 50 mM Tris-HCl buffer (pH 7.4) containing (mM): NaCl (120), KCl (5) 
Statistical Analysis
Two-way analysis of variance (ANOVA) with each autoradiographic assay initially tested for effects of drug treatments in preselected brain regions; given overall significance, post-hoc Dunnett t-tests identified significant differences between treatment groups. Unless stated otherwise, data are presented as means Ϯ SEM. Comparisons were considered significant at p Ͻ 0.05 in two-tailed tests, with degrees of freedom (df) based on N subjects/treatment group.
RESULTS
Preliminary experiments with transfected cell membranes (Table 1) confirmed that the new D 4 ligand L-745,870 (Kulagowski et al. 1996; Kebabian et al. 1997) showed expected high D 4 affinity and selectivity, whereas clozapine and (ϩ)-NPA had similar and more moderate D 4 affinity, though (ϩ)-NPA had somewhat higher D 4 - Figure 1 . Sites for autoradiographic analyses of rat brain regions. Samples included 10 m coronal sections from: A (A 3.2-4.2), B (A 1.7-2.2), C (A 0.7-1.2), and D (A 0.2Ϫ0.7 mm anterior to bregma according to Paxinos and Watson, 1982 (Tables 6  and 7) were highly correlated (r ϭ 0.93; slope ϭ 0.95, p Ͻ 0.0001).
To summarize, when [ 
DISCUSSION
The present autoradiographic findings indicate that in the rat's ACC and CPu tissues, fluphenazine pretreat- (Wong et al. 1986; Farde et al. 1990; Murray et al. 1995; Sumiyoshi et al. 1995; Neve and Neve 1997) . Nemonapride and spiperone have relatively high affinity for cloned D 2 , D 3 , and D 4 receptors expressed in genetically transfected cells (Ki ϭ 0.07-0.61 nM) (Sokoloff et al. 1990; Van Tol et al. 1991) , whereas raclopride has high affinity (1.8 and 3.5 nM) for cloned D 2 and D 3 receptors, but much lower affinity for cloned D 4 receptors (2.0 M) . The difference in radioligand binding defined by nemonapride or spiperone compared to raclopride may correspond to D 4 -like receptors or binding sites .
The differential affinity of DA antagonists to specific types of D 2 -like receptors led to the present assays based on including a saturating concentration of raclopride to occlude D 2 and D 3 receptors selectively, so that the remaining binding of [ (Tables 6  and 7) .
With both radioligands, D 4 -like binding density (fmol/mg) in untreated brain tissue was less in cerebral cortex than in ACC and CPu (Tables 6 and 7) but represented a somewhat higher proportion of all D 2 -like receptor binding in the cortex than in ACC or CPu (Tables  2, 3 , 6, and 7). Higher levels of D 4 -like binding in ACC and CPu than in frontal cortex contrast with more abundant expression of D 4 mRNA in cerebral cortex than in subcortical regions of rat and human forebrain (Van Tol et al. 1991; Meador-Woodruff 1994 , 1996 . Some D 4 -like sites in ACC and CPu may arise on afferent axons with cell bodies in cerebral cortex as well as on intrinsic local neurons ) and expression of D 4 receptor immunoreactivity has been found in glutamatergic pyramidal cells as well as intrinsic GABAergic neurons in primate cortex (Mrzljak et al. 1996) . Failure of typical and atypical antipsychotics to significantly upregulate cortical D 4 -like sites (Tables 6  and 7 ) may suggest regional differences in the regulation of D 4 genes or protein synthesis and turnover. This suggestion is consistent with a reported lack of increase of both D 4 mRNA and receptor protein in rat cortex after treatment with haloperidol, in contrast to a coordinated rise of both message and product in rat striatum (Schoots et al. 1995) .
Increased binding of [ (Tables 2 and 3) probably reflects a selective increase in D 2 receptors, since cortical D 4 -like binding was not altered by these drugs (Tables 6 and 7) and D 3 receptors are infrequent in rat cortex (Sokoloff et al. 1990) . Some upregulation of D 2 receptors in cerebral cortex in response to repeated treatment with both atypical and typical antipsychotic agents has also been found in rats and primates (Janowsky et al. 1992; Lidow and Goldman-Rakic 1994) . Selective increases in MPC, but not CPu or ACC, D 2 receptors after treatment with the atypical agents clozapine and (ϩ)-NPA (Tables 2  and 3 ) may reflect differences in the types of D 2 -like receptors in these brain regions or different regulatory responses of cells which express them.
Neither D 2 nor D 3 receptor upregulation was detected in CPu or ACC after long-term treatment with clozapine or (ϩ)-NPA, and fluphenazine evidently increased D 2 but not D 3 binding (Tables 4 and 5 (Table 5) , consistent with previous findings after antipsychotic treatment (Levésque et al. 1995; ). Lack of a response of D 3 receptors to repeated treatment with DA antagonists may reflect their inability to upregulate in response to prolonged blockade, perhaps paralleling their limited or inconsistent interactions with G-proteins and second- (Sokoloff et al. 1990; Baldessarini and Tarazi 1996) .
Regarding D 4 receptors, three weeks of treatment with a typical antipsychotic (fluphenazine), as well as a prototype (clozapine) and a candidate atypical antipsychotic agent ([ϩ]-NPA), all produced consistent increases in abundance of D 4 -like binding in some subcortical regions of rat forebrain (CPu and ACC), but not in OT or cerebral cortex (Tables 6 and 7) , in accord with results obtained with another typical neuroleptic, haloperidol (Shoots et al. 1995; Florijn et al. 1997; . All three test agents used in this study have high affinity to cloned D 4 receptors expressed in transfected cells (Ki ϭ 10-60 nM) (Van Tol et al. 1991; (Table 1) . Increases in D 4 -like binding in CPu and ACC following all three treatments evidently reflect increased tissue density of D 4 receptors (upregulation) and perhaps supersensitivity, as occurs with D 2 receptors after treatment with D 2 antagonists and other anti-DA treatments (Creese et al. 1977; Campbell et al. 1993; Baldessarini and Tarazi 1996) .
Apparent increases of D 4 -like binding by both typical and atypical antipsychotic agents suggests that D 4 receptors may be a common site of mediation of drug antipsychotic effects. Moreover, clozapine-induced increases, and possibly supersensitivity, of D 4 receptors may contribute to a high risk of psychotic exacerbation after discontinuing clozapine treatment of chronically psychotic patients ). In addition, reported elevations of D 4 -like receptors in postmortem brain tissue from patients with schizophrenia Murray et al. 1995; Sumiyoshi et al. 1995) may include adaptations to antipsychotic drug exposure, although some studies failed to detect D 4 -like receptor upregulation in such patients (Reynolds and Mason 1994, 1995; . Clarification of a role of D 4 receptors in the pathophysiology and treatment of psychotic disorders, and details of their regional regulation following long-term antipsychotic treatment in various species await further improvements in the assay of D 4 receptor proteins, including selective radioligands or antibodies (Kebabian et al. 1997 ).
In conclusion, striatolimbic D 4 -like binding sites that appear to be accounted for mainly by D 4 receptors, as well as medioprefrontal cortical D 2 -like receptors, may constitute attractive targets for guiding development of novel psychotropic drugs. Lower occupancy of D 2 receptors in neostriatum (CPu) by atypical antipsychotic agents may contribute to their low risk of neurological side effects. Current findings of similar long-term effects of (ϩ)-NPA and clozapine on different D 2 -like DA receptor subtypes in specific regions of mammalian brain add evidence of the unique properties of such drugs and specifically encourage further consideration of S(ϩ)-aporphines as potential atypical antipsychotic agents.
